PAL-test for malignant disease.
Peripheral blood lymphocytes from a total of 300 subjects including normal controls and patients with malignant and non-malignant disorders were investigated to determine their ability to agglutinate with Poly-l-lysine 3400 (PAL-test). A high level of association between clinically evident cancer and a positive reaction was confirmed. Lymphocytes from 72 of 90 patients with malignant diseases as well as 33 of 140 patients with non-malignant processes showed positive reactions. All healthy controls were negative. The positive evidence of the PAL-test amounted to over 80%. The results and possible mechanisms of the PAL-test are discussed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000372:Agglutination Tests; D001963:Bromelains; D002648:Child; D002675:Child, Preschool; D005260:Female; D005688:Galactosamine; D006801:Humans; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000175:diagnosis*; D009439:Neuraminidase; D010206:Papain; D010434:Pepsin A; D010455:Peptides; D011107:Polylysine; D011230:Precancerous Conditions / Q000175:diagnosis
D010455:Peptides; D011107:Polylysine; D005688:Galactosamine; D001963:Bromelains; D009439:Neuraminidase; D010206:Papain; D010434:Pepsin A